We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Breath Test Could Help Detect Blood Cancers

By LabMedica International staff writers
Posted on 24 Jul 2025

Blood cancers affect thousands of people annually, with around 40,000 new diagnoses and 16,000 deaths each year in the UK alone. More...

Diagnosing these cancers can be especially difficult in the early stages, as symptoms like fatigue and weight loss are vague and nonspecific. Current diagnostic methods rely on specialized tests such as imaging scans or biopsies, which are often costly, time-consuming, and not readily available in many regions. This lack of accessible and rapid testing limits early detection, which is crucial for successful treatment outcomes. Researchers have now identified certain molecules exhaled in the breath that could indicate the presence of blood cancers, opening the door to a non-invasive, low-cost, and rapid testing alternative.

Researchers from Queen Mary University of London (London, UK) conducted a study using a breathalyser technology called Breath Biopsy, developed by Owlstone Medical (Cambridge, UK). In the trial, the team collected exhaled breath samples from 46 people with blood cancer and 28 healthy individuals. The breath samples were analyzed using mass spectrometry to identify thousands of molecular fragments and establish chemical fingerprints. The study focused particularly on high-grade lymphoma, an aggressive form of blood cancer, and found significantly elevated levels of certain molecules in patients' breath. These molecules are associated with oxidative stress, a process linked to cell damage and cancer development. The goal was to determine whether blood cancer cells release molecules that transfer into the breath, offering a novel detection method.

Published in HemaSphere, the study showed for the first time that breath analysis could help detect blood cancers. The simplicity, portability, and affordability of breathalyser devices offer significant advantages, especially in low-resource settings that lack access to specialized diagnostic infrastructure. These devices could help monitor treatment progress and reduce dependency on expensive scans. Further research will focus on understanding how these airborne molecules are produced and determining which subtypes of lymphoma are most detectable through this method. The team also aims to shorten breath collection times from 10 minutes to just a few seconds and improve the sensitivity and specificity of future breath tests.

“In future, rather than sending patients away for costly scans and waiting for test results, doctors may be able to conduct a quick breath test in their clinic room and potentially have the results within a few seconds,” said Dr. John Riches, lead researcher of the study.

Related Links;
Queen Mary University of London
Owlstone Medical


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image Credit: iStock

Global TB Summit Connects Diagnostic Testing With Prevention and Clinical Care

Tuberculosis remains a major global infectious disease challenge despite declining deaths. In 2024, an estimated 10.7 million people worldwide developed the disease and nearly 1.2 million died from it.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.